Sorrento Therapeutics Inc. (NASDAQ: SRNE) gained 1.6% after announcing the UK’s regulatory agency Medicines and Healthcare products Regulatory Agency cleared its COVI-DROPS candidate for a second phase efficacy study. MHRA clears Sorrento’s COVI-DROPS Application The company submitted the application as a rolling application with the MHRA clearing the trial within […]